Drugs / ODM-103
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01688089 | Sep 2012 → Sep 2014 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-103 | “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers” NCT01688089 ↗ |
| Route | Oral | “Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days” NCT01688089 ↗ |